Complete revascularization in acute myocardial infarction. 1 culprit lesion , then all the others

Original title: Randomized Trial of Preventive Angioplasty in Myocardial Infarction (PRAMI trial). Referencia: David S. Wald et al. N Engl J Med 2013.DOI: 10.1056/NEJMoa1305520.

Patients developing ST segment elevation myocardial infarction are effectively treated with primary angioplasty to responsible artery . It is unclear whether revascularized other significant lesions in other non culprit vessels  will prevent future events and in fact,  guides advise against it except when we are in the context of shock. The aim of this single-blind randomized trial was to evaluate whether practice preventive angioplasty in other injuries as part of primary angioplasty over the responsible artery may decrease the composite of cardiac death , myocardial infarction or refractory angina.

Between 2008 and 2013, 465 patients suffering ST segment elevation myocardial infarction were successfully treated for the responsible artery and that also had other lesions ≥ 50 % possibility of revascularization added for hemodynamic stability ( we excluded patients with left main coronary artery injury, chronic total occlusions and cardiogenic shock ) . Once primary angioplasty was completed we randomized remaining lesions to immediate preventive angioplasty  or terminate the procedure. Angioplasty in stages was discouraged and the only reason to revascularize non culprit injuries in the control branch was refractory angina with demonstrated ischemia. On January 24th, 2013 the trial was stopped early for the recommendation of the safety committee  given the significant difference in the primary end point for the preventive angioplasty branch . 

At the end of the study per mean of 23 months, the primary endpoint ( combined cardiac death, myocardial infarction and refractory angina ) was observed in 21 of 234 patients in the preventive angioplasty branch versus 53 of 231 patients in the control branch ( RR 0.35 , CI 0.21 to 0.58 , p < 0.001). The effect was similar in magnitude and highly significant when performing the analysis considering only cardiac death and myocardial infarction ( RR 0.36 , CI 0.18 to 0.73 , P = 0.004 ) . 

Conclusion:

In this randomized trial, we observed that  after successful primary angioplasty , perform the same procedure concomitantly of preventive angioplasty to other arteries with significant lesions but not responsible for the heart attack reduces adverse cardiovascular event risk compared with single angioplasty  limited to the responsible artery. 

Editorial Comment

This study does not answer the question about deferred angioplasty (a common practice in many centers ), where primary angioplasty is performed only in the culprit artery but in the same placement ( 48-72 hours later) completes the non culprit vessel revascularization. In this sense protocol was very rigid allowing angioplasty to other vessels in the control branch only in the context of refractory angina and ischemia determined . 

SOLACI.ORG

More articles by this author

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural...

PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI

Inflammation plays a key role in the onset and progression of atherosclerosis and has been linked to a higher risk of cardiovascular events, regardless...

Aspirin vs. Clopidogrel Monotherapy After 1 Month of ACS: Subgroup Analysis Based on Bleeding Risk and MI Type

Current guidelines still recommend dual antiplatelet therapy (DAPT) for 12 months following percutaneous coronary intervention (PCI) as the standard treatment in patients with acute...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Polymer-Free vs. Biodegradable Polymer Stents: SORT OUT IX 5-Year Outcomes

In a constant strive to achieve life time management, interventional cardiologists focus on optimizing coronary scaffolds, which calls for the development of devices with...

Three-Year Outcomes of Mitral Valve-in-Valve Therapy with Balloon-Expandable Valves in the United States

Gentileza del Dr. Juan Manuel Pérez. Mitral Valve-in-Valve (MViV) implantation with balloon-expandable valves has become a solid alternative for patients with degenerated mitral bioprostheses. However,...

Edge-to-Edge Treatment in Cardiogenic Shock

Cardiogenic shock (CS) is characterized by severe ventricular dysfunction, most often of ischemic origin. It is frequently associated with severe mitral regurgitation (MR), either...